EUCTR2009-012576-27-SI进行中（未招募）1 期
Evaluation of Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma - SORAMIC
Medical Faculty, University Magdeburg0 个研究点目标入组 665 人开始时间: 2010年11月9日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 665
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Age: 18-85 years
- •2.Hepatocellular carcinoma
- •3. If extrahepatic metastases: liver-dominant disease
- •4.Stage BCLC A, B, or C
- •5.Child-Pugh A, Child-Pugh B up to 7 points
- •6.Willing to comply with all study procedures
- •7.Has voluntarily given written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.If female, pregnant or breast feeding (females of child-bearing potential must use adequate contraception and must have a negative pregnancy test performed within 7 days prior to inclusion into this study)
- •2.If male, not using adequate birth control measures
- •3.One or more of the following:
- •-Hemoglobin <10g/dL,
- •-WBC <2,500 cells/mm3,
- •-ANC <1,500 cells/mm3,
- •-platelets <50,000/mm3,
- •-ECOG performance status >2
- •4.Life expectancy <16 weeks
- •5.Pulmonary metastases
- •6.Patients with known GFR <30 mL/min/1.73m2
- •7.PT-INR/PTT >1.5 times the upper limit of normal
- •8.uncontrolled infections at the time of microtherapy
- •9.Child-Pugh score >7 points;
- •10.Uncontrolled ascites
- •11.tumor load of the whole liver >70%
- •12.Contraindications for study medications according to product labeling or procedures
- •13.Having undergone surgical procedures with resection of the sphincter of Oddi
- •14.Significant cardiovascular disease; e.g., myocardial infarction within 6 months of inclusion, chronic heart failure (New York Heart Association class III or IV), unstable coronary artery disease
- •15.Uncontrolled hypertension
- •16.Thrombotic or embolic events including transient ischemic attacks within the past 6 months
- •17.History of hemorrhage / bleeding events of grade 3 or worse
- •18.Previous variceal bleeding within the past 3 months
- •19.Previous malignancy other than carcinoma in situ of the skin or the cervix uteri within 5 years prior to inclusion
- •20.History of organ transplant (including prior liver transplantation)
- •21.HIV, congenital immune defect, any immunosuppressive therapy for autoimmune disease (rheumatoid arthritis) or inflammatory bowel disease
- •22.Mental conditions rendering the subject incapable to understand the nature, scope, and consequences of the trial
- •23.Close affiliation with the investigational site; e.g. first-degree relative of the investigator.
- •24.Participating in another therapeutic clinical trial or has completed study participation in another therapeutic clinical trial within 30 days of enrolment into this trial
- •25.Having been previously enrolled in this clinical trial
研究者
相似试验
进行中（未招募）
1 期
Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA (Primovist) enhanced MRI in patients with inoperable liver cancer (SORAMIC)EUCTR2009-012576-27-PLMedical Faculty, University Magdeburg710
进行中（未招募）
1 期
Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA (Primovist) enhanced MRI in patients with inoperable liver cancer (SORAMIC)EUCTR2009-012576-27-ATMedical Faculty, University Magdeburg710
进行中（未招募）
1 期
Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA (Primovist) enhanced MRI in patients with inoperable liver cancer (SORAMIC)Patients with Hepatocellular carcinoma (liver-predominant disease)MedDRA version: 16.1 Level: LLT Classification code 10019829 Term: Hepatocellular carcinoma recurrent System Organ Class: 100000004864MedDRA version: 16.1 Level: LLT Classification code 10049010 Term: Carcinoma hepatocellular System Organ Class: 100000004864MedDRA version: 16.1 Level: LLT Classification code 10019828 Term: Hepatocellular carcinoma non-resectable System Organ Class: 100000004864MedDRA version: 16.1 Level: LLT Classification code 10019830 Term: Hepatocellular carcinoma resectable System Organ Class: 100000004864EUCTR2009-012576-27-NLMedical Faculty, University Magdeburg665
进行中（未招募）
不适用
Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA (Primovist) enhanced MRI in patients with inoperable liver cancer (SORAMIC)Patients with Hepatocellular carcinoma (liver-predominant disease)MedDRA version: 18.0Level: LLTClassification code 10019829Term: Hepatocellular carcinoma recurrentSystem Organ Class: 100000004864MedDRA version: 18.0Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 100000004864MedDRA version: 18.0Level: LLTClassification code 10049010Term: Carcinoma hepatocellularSystem Organ Class: 100000004864MedDRA version: 18.0Level: LLTClassification code 10019830Term: Hepatocellular carcinoma resectableSystem Organ Class: 100000004864EUCTR2009-012576-27-BEMedical Faculty, University Magdeburg710
进行中（未招募）
1 期
Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA (Primovist) enhanced MRI in patients with inoperable liver cancer (SORAMIC)Patients with Hepatocellular carcinoma (liver-predominant disease)MedDRA version: 18.0 Level: LLT Classification code 10019829 Term: Hepatocellular carcinoma recurrent System Organ Class: 100000004864MedDRA version: 18.0 Level: LLT Classification code 10049010 Term: Carcinoma hepatocellular System Organ Class: 100000004864MedDRA version: 18.0 Level: LLT Classification code 10019828 Term: Hepatocellular carcinoma non-resectable System Organ Class: 100000004864MedDRA version: 18.0 Level: LLT Classification code 10019830 Term: Hepatocellular carcinoma resectable System Organ Class: 100000004864EUCTR2009-012576-27-GBMedical Faculty, University Magdeburg710